OA-29 Mezigdomide (MEZI), Tazemetostat (TAZ), and Dexamethasone (DEX) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results From the CA057-003 Trial

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI:10.1016/S2152-2650(24)01870-6

Luciano Costa, Rakesh Popat, David Siegel, Fredrik Schjesvold, Saad Usmani, Nizar J. Bahlis, Albert Oriol, Michael Chu, Syed Abbas Ali, Karthik Ramasamy, Monique Hartley-Brown, Joaquín Martínez-Lopez, Allison Gaudy, Antonina Kurtova, Wen Zhang, Rafael Sarmiento, August Dietrich, Jessica Katz, Michael Pourdehnad, Paul Richardson

引用次数: 0

查看原文本刊更多论文

OA-29 Mezigdomide (MEZI)、Tazemetostat (TAZ) 和地塞米松 (DEX) 用于复发性/难治性多发性骨髓瘤 (RRMM) 患者 (pts)：CA057-003 试验的初步结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.